NXEN Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Seelos Therapeutics Inc

Watchlist Manager

Watchlist

Price: 0.025 EUR -90.23% Market Closed

Market Cap: €24.8m

S	Seelos Therapeutics Inc F:NXEN	US
	Sprint Bioscience AB F:5JA1	SE
	Draegerwerk AG & Co KGaA F:DRW8	DE
	FibroGen Inc NASDAQ:KYNB	US
	Unicaja Banco SA F:7UB	ES
	Goodtech ASA OSE:GOD	NO
F	First Helium Inc F:2MC	CA
	Fleury Michon SA F:4XZ	FR
	Seco SpA F:7GV	IT
	KBC Groep NV OTC:KBCSY	BE
	Zydus Lifesciences Ltd BSE:532321	IN
C	Coloplast A/S XETRA:CBHD	DK
M	Markel Corp F:MKV	US
	Galapagos NV AEX:GLPG	BE

Profitability Summary

Seelos Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-1 480%

Negative 3Y Average Operating Margin

-2 671%

Operating Margin is Increasing

-8 148% > -1 480%

Exceptional Net Margin

203%

Negative 3Y Average Net Margin

-2 657%

Net Margin is Increasing

-9 030% > 203%

Negative Free Cash Flow Margin

-659%

Negative 3Y Average Free Cash Flow Margin

-1 693%

Free Cash Flow Margin is Increasing

-6 795% > -659%

Negative ROE

-11%

Exceptional 3Y Average ROE

Exceptional 3Y Average ROIC

1 399%

ROIC is Increasing

-1 265% > 426%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.